Margolis-FDA Workshop: Identifying Key Competencies for Opioid Prescriber EducationRegister
Contact InformationLuke Durocher
MaterialsFINAL Agenda Key Competencies for Opioid Prescriber Education.pdf (188.57 KB)
FINAL Meeting Summary Key Competencies for Opioid Prescriber Education.pdf (233.48 KB)
FINAL Research Primer Key Competencies for Opioid Prescriber Education_0.pdf (261.21 KB)
FINAL Discussion Guide Key Competencies for Opioid Prescriber Education.pdf (169.09 KB)
Identifying Key Competencies for Opioid Prescriber Education Slide Deck.pdf (13.7 MB)
Speaker Biographies Key Competencies for Opioid Prescriber Education.pdf (480.13 KB)
Margolis-FDA Workshop: Identifying Key Competencies for Opioid Prescriber Education
April 4, 2022, 1:00-5:00 p.m. ET | April 5, 2022, 1:00-4:10 p.m. ET
Duke-Margolis and the U.S. Food and Drug Administration (FDA) are collaborating to host a two-day virtual public workshop focused on identifying gaps in existing opioid prescriber education offerings and core competencies that should be included in educational content for opioid prescribers and other healthcare providers, including prescriber education under a Risk Evaluation and Mitigation Strategy (REMS). Please join us on April 4th and 5th for a workshop which will bring together federal agencies, provider associations, licensing and accrediting organizations, education experts, and other key stakeholders aiming to alleviate the opioid and substance use crisis through improved education for opioid prescribers and other healthcare providers.
Key topics explored through workshop discussions will include: 1) Examining Core Competencies for Opioid Prescriber Education, 2) Professional Practice Gaps in Substance Use Disorder and Pain Management, and Related Gaps in Current Prescriber Education, 3) Identifying Lessons Learned from Provider Education and Continuing Medical Education Initiatives, and 4) Future Directions and Next Steps for Shaping Prescriber Education Efforts. This workshop will build on discussions from an October 2021 Margolis-FDA convening on REMS opioid prescriber education.